Advertisement

Topics

Adenosine Deaminase - Biotech, Pharma and Life Science Channel

02:03 EDT 4th May 2016 | BioPortfolio

PubMed Articles [427 Associated PubMed Articles listed on BioPortfolio]

Mitochondrial transplantation for therapeutic use.

Mitochondria play a key role in the homeostasis of the vast majority of the body's cells. In the myocardium where mitochondria constitute 30 % of the total myocardial cell volume, temporary attenuati...

Narrow QRS tachycardia with varying VA and RR intervals: What is the mechanism?

A 45-year-old woman was referred for radiofrequency catheter ablation of narrow QRS tachycardia that was terminated with intravenous adenosine. Twelve-lead ECG was normal during sinus rhythm. She was ...

Regulation of allergic inflammation by the ectoenzyme E-NPP3 (CD203c) on basophils and mast cells.

Adenosine 5'-triphosphate (ATP) is released from dying or damaged cells, as well as from activated cells. Once secreted, extracellular ATP induces several immune responses via P2X and P2Y receptors. B...

Radiation Promptly Alters Cancer Live Cell Metabolic Fluxes: An In Vitro Demonstration.

Quantitative data is presented that shows significant changes in cellular metabolism in a head and neck cancer cell line 30 min after irradiation. A head and neck cancer cell line (UM-SCC-22B) and a c...

5'-Substituted amiloride derivatives as allosteric modulators binding in the sodium ion pocket of the adenosine A2A receptor.

The sodium ion site is an allosteric site conserved amongst many G protein-coupled receptors (GPCRs). Amiloride 1 and 5-(N,N-hexamethylene)amiloride 2 (HMA) supposedly bind in this sodium ion site and...

A CIEF-LIF method for simultaneous analysis of multiple protein kinases and screening of inhibitors.

Here, a CIEF-LIF method for multiple protein kinase simultaneous analysis and inhibitors throughput screening with fast rate and low cost is presented. Comparing with CZE, CIEF-LIF exhibited great foc...

Narrow QRS Tachycardia With Spontaneous Switch. What is the Mechanism?

A 45-year-old woman was referred for radiofrequency catheter ablation of narrow QRS tachycardia that was terminated with intravenous adenosine. Twelve-lead ECG was normal during sinus rhythm and trans...

Dose-Dependent Neuroprotective Effect of Caffeineon a Rotenone-Induced Rat Model of Parkinsonism: A histological study.

Several lines of evidence have demonstrated an inverse relationship between caffeine utilization and Parkinson's disease (PD) progression. Caffeine is a methylxanthine known as a non-specific inhibito...

Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.

HSP70 is a molecular chaperone and a key component of the heat shock response. Due to its proposed importance in oncology, this protein has become a popular target for drug discovery, efforts which ha...

ABC transporters affect the elimination and toxicity of CdTe quantum dots in liver and kidney cells.

This paper aimed to investigate the role of adenosine triphosphate-binding cassette (ABC) transporters on the efflux and the toxicity of nanoparticles in liver and kidney cells. In this study, we synt...

News Articles [85 Associated News Articles listed on BioPortfolio]

Orchard Therapeutics Launches and Announces Academic Partnerships for Development of Transformative Gene Therapies

London, UK, May 3, 2016 / B3C newswire/ – ORCHARD THERAPEUTICS, a clinical-stage biotechnology company with operations in London and the United States, has officially launched today with a £21-mil...

Performing Cyclic AMP HTRF Screening Assays

G-protein coupled receptors (GPCRs) are a major class of targets for drug discovery. Cyclic AMP (cyclic adenosine 3′,5′-monophosphate) is a second messenger and one of the most important...

Evotec and ex scientia join forces to discover bispecific small molecule immuno-oncology therapeutics

Initial focus will be cancer-related adenosine targets which are increasingly recognised to play important roles in immuno-oncology

Base pair editing to correct point mutations using a nuclease-dead CRISPR-associated protein 9 (Cas9) variant conjugated to a cytidine deaminase

A CRISPR-based method of editing base pairs could correct point mutations more efficiently than traditional CRISPR-

Frontier IP investee firm in tie up to find next wave of cancer drugs

Frontier IP Group Plc (LON:FIPP) investee company ex scientia is teaming up with Germany’s Evotec discover the next wave of immuno-oncology drugs that use the body’s immune system to attack the ki...

Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage

Current genome-editing technologies introduce double-stranded (ds) DNA breaks at a target locus as the first step to gene correction. Although most genetic diseases arise from point mutations, current...

INNATE PHARMA: First-in-class CD39 checkpoint inhibitor presented at the AACR meeting

Novel, potent anti-CD39 antibody, IPH52, validated in preclinical models. Marseille and Lyon, April 19, 2016 Innate Pharma and OREGA Biotech today presented preclinical data on I...

Innate Pharma presents new CD73 checkpoint inhibitor program

Novel antibodies identified that block the CD73 immune checkpoint for cancer immunotherapy; Strengthens Innate's positioning in targeting the tumor microenvironment. Marseille...

Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment

SAN DIEGO, April 18, 2016 /PRNewswire/ -- Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for...

Kymab and Heptares collaborate for immuno-oncology project

Monoclonal antibody pharma company Kymab has announced a collaboration with Sosei subsidiary Heptares Therapeutics to develop immuno-oncology drugs.The companies will combine their expertise to discov...

Events [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. ...

ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum produ...

Clinical Trials [117 Associated Clinical Trials listed on BioPortfolio]

High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay

High on-treatment platelet reactivity to adenosine diphosphate was a important reason to cause ischemic events in antiplatelet therapy. Using single testing to definite HPR may miss the "t...

Adenosine as an Adjunct to Blood Cardioplegia

Myocardial protection is a major issue in cardiac surgery, since inadequate protection increases the risk of postoperative cardiac dysfunction. The main principle of myocardial protection ...

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

This is a proof of concept study (a study to initially assess the benefit a new drug indication) of the combination of two investigational drugs cediranib and olaparib in patients with ova...

Oral THU-Decitabine + Nivolumab for Advanced Non-Small Cell Lung Cancer

This study looks at the effect of three drugs on lung cancer tumors. This study includes two groups of patients randomized to either Nivolumab, which is the standard of care for this lung ...

Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab

This is a phase 1/1b open-label, multicenter, dose-selection study of CPI-444, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune sy...

A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.

This study is the second Phase-II trial analyzing efficacy outcomes of PBF-680 in asthmatic subjects, following the supportive data from the proof-of-concept trial on the effect of PBF-680...

Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer

Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to a...

Comparing Ticagrelor Versus Clopidogrel on Microcirculation

Recently, data (PLATO) from an AstraZeneca study of platelet inhibition and patient outcomes, a Phase III pivotal efficacy and safety study with a duration of up to 12 months comparing tic...

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Rationale: In patients suffering a myocardial infarction the P2Y12 receptor antagonists prasugrel and ticagrelor improve outcome and prognosis compared to clopidogrel. Moreover, ticagrelo...

Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation

This study is a randomized, open-label, controlled study that will explore the efficacy of adjuvant chemotherapy based on the adenosine triphosphate tumor chemosensitivity assay for patien...

Videos

None available.

Medical and Biotech [MESH] Definitions

Drugs that inhibit ADENOSINE DEAMINASE activity.

An enzyme that catalyzes the hydrolysis of adenosine to inosine with the elimination of ammonia. Since there are wide tissue and species variations in the enzyme, it has been used as a tool in the study of human and animal genetics and in medical diagnosis. EC 3.5.4.4.

A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.

A ribonucleoside antibiotic synergist and adenosine deaminase inhibitor isolated from Nocardia interforma and Streptomyces kaniharaensis. It is proposed as an antineoplastic synergist and immunosuppressant.

A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.

Quick Search
Advertisement
 
review and buy Adenosine Deaminase market research data and corporate reports here

Channels Quicklinks